VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH MDS 2021 | Immunological impact of TP53 in MDS

Shahram Kordasti, MD, PhD, King’s College London, London, UK, discusses the immunological effects of TP53 mutations in myelodysplastic syndromes (MDS) and how these impact prognosis. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter